- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00707928
Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study
Primary objective The primary objective of this study is to see whether intravenous (IV) NTG 100-200 microgram can effectively help extract retained placenta as compared to placebo, in a randomized controlled multicenter study.
Secondary objective is to compare the hypotensive effects of NTG as compared to placebo, including others side effects such as headache, blood loss, or others.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After the approval of the Ethical committee of each institute, and consent signed by the patient, 100 patients with retained placenta were divided into 2 groups in 5 tertiary care centers, university hospitals. By using the program research randomizer (from www. Randomizer.org/form.htm), with the block of 10 and the numbers within the concealed envelopes, totally 100 patients with retained placenta will be divided into 2 groups to have either 100-200 microgram of IV, NTG or IV placebo. Due to unequal number of the cases enrolled in each centers, they will receive 10 envelopes for 10 cases (5 NTG and 5 placebo) at a time. When they finish the first 10 cases, they will start another 10 cases of the next set until all 10 sets has been started. Each of 5 centers might enroll the cases between 10 to 40 cases up to their populations..
Once a diagnosis of retained placenta has been made ( ≥ 30 min after delivery), Hematocrit will be checked and IV crystalloid solution 500 ml has been rapidly perfuse and noninvasive monitored included pulse oximetry, electrocardiogram and noninvasive blood pressure will be monitored.
Patients with signs of hypovolemia ( SBP < 100 mmHg, or pulse > 100/min), or ASA classification > II will be excluded from the study.
First step: In the treatment group, 100 microgram of NTG will be given and wait for 80 seconds ( maximum relaxation effects of IV NTG)(5,6) before starting gently cord traction (1min). If the placenta can not be extracted, another 100 microgram NTG from the same syringe will be given and wait for another 80 seconds before starting another extraction (1min), If the placenta can not be extracted, it will be considered failed. In the placebo group, NSS will be used instead of NTG.
Second step: To give a chance for patients in placebo group, another syringe with 200 microgram will be given as in the first step for the placebo group. In the treatment group, NSS will be used instead of NTG. The outcome in the second step will not be included in the first step.( The solutions in both syringes which will be prepared by the research assistant who will not involve in the study, will be blinded to the patient, the obstetrician, the anesthesiologist and the investigator) General anesthesia will be used for manual removal of placenta in cases that placenta can not be extracted after the second step.
Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
Vital signs will be recorded before the first NTG bolus and thereafter at 1 min interval for 5 min then every 2 min for 10 min then every 5 min. for 20 min(see the CRF).
The patient will be followed up closely for 24 h postoperatively and Hct will be checked , including the final results upon discharge home.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10700
- Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy pregnant patient (ASA classification I ,II )
- Normal pregnancy with at least 28 week gestation
Exclusion Criteria:
- ASA classification III and up
- Having complication of pregnancy such as hypertensive disease of pregnancy,
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 1
1=nitroglycerine 100 microgram intravenous100-200 microgram of IV.
|
nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered.
Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
Other Names:
|
PLACEBO_COMPARATOR: 2
2=placebo with the same volume as NTG 100-200 microgram of IV.
|
NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered.
Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
successful of placenta extraction
Time Frame: 5 mintues
|
5 mintues
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
hypotension
Time Frame: 20 mintues
|
20 mintues
|
headache
Time Frame: 2 hour
|
2 hour
|
blood loss
Time Frame: 24 hour
|
24 hour
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shusee Visalyaputra, MD, Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Si249/2007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retained Placenta
-
Bait Balev HospitalMaccabi Healthcare Services, IsraelCompletedRetained Product of Pregnancy
-
University Hospital, BordeauxCompletedRetained PlacentaFrance
-
Hawler Medical UniversityCompleted
-
Charite University, Berlin, GermanyRecruitingPlacenta; RetentionGermany
-
Eslam Mohammed AbbasUnknownPostpartum Haemorrhage With Retained PlacentaEgypt
-
Hadassah Medical OrganizationUnknown
-
University of EdinburghNHS Lothian; University of AberdeenCompleted
-
Hawler Medical UniversityCompletedPostpartum Haemorrhage | Retained PlacentaIraq
-
Wilson LiambilaMerck Sharp & Dohme LLCCompletedPostpartum Hemorrhage | Puerperal Sepsis | Preeclampsia and Eclampsia | Retained Placenta, Without Hemorrhage | Obstructed Labor Due to Breech PresentationKenya
-
University Hospital, Clermont-FerrandUniversité d'Auvergne; Jacques Lacarin Hospital Center; CRRF La Châtaigneraie; CH... and other collaboratorsUnknownPostpartum Hemorrhage | Maternal Morbidity | Delivery | Postpartum Endometritis | Retained PlacentaFrance
Clinical Trials on nitroglycerine
-
Danish Headache CenterEUROHEADCompletedFamilial Hemiplegic MigraineDenmark
-
United States Naval Medical Center, San DiegoUnknownCOLIC | BILIARY TRACT DISEASESUnited States
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingIschemic Heart Disease | Hypotension SymptomaticTaiwan
-
Shaanxi Buchang Pharmaceutical Co., LtdUnknownAngina, StableChina
-
University of California, Los AngelesTerminatedIschemic Stroke | Intracerebral HemorrhageUnited States
-
Alexandria UniversityRecruitingPersistent Pulmonary Hypertension of the Newborn | Respiratory Disease | EchocardiographyEgypt
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)CompletedRheumatoid ArthritisUnited States
-
University of ZurichCompletedHypertension | Heart TransplantationSwitzerland
-
Kasr El Aini HospitalCompletedRadial Artery Injury PrevetionEgypt
-
First People's Hospital of ChenzhouNot yet recruitingHepatectomy | Sildenafil | Hemodynamics Instability | Central Venous PressureChina